Public trial registry of the CCC-Munich

Trial ADAPT Triple positive (TPII)

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ADAPT Triple positive (TPII)
World
Full title
:

Eine offene, prospektive, randomisierte, multizentrische Vergleichsstudie einer präoperativen Trastuzumab/Pertuzumab Kombinationstherapie mit gleichzeitiger Taxan Chemotherapie oder endokriner Therapie über 12 Wochen und Beurteilung der Lebensqualität einer Trastuzumab, Pertuzumab Therapie in Kombination mit einer (neo) adjuvanten Standardbehandlung bei Patientinnen mit operablem HER2+/HR+ Brustkrebs.

World
EudraCT number
:
World
Responsible organization
:
Frauenklinik IN, Telefon: 089440054111 Lmu
Indications
Classification Code Description
- Breastcancer
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
Status
World
Status
:
Trial finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.